Trinity Biotech Falls Below $15M Public Float Requirement, Faces Nasdaq Delisting Risk
Trinity Biotech received a Nasdaq notice on February 19, 2026, after its MVPHS dropped below the $15 million requirement for 30 business days. The company has until August 18, 2026 to exceed $15 million in MVPHS for ten days or face delisting or a transfer to Nasdaq Capital Market.
1. Nasdaq Non-Compliance Notice
On February 19, 2026, Trinity Biotech was notified by Nasdaq that its market value of publicly held shares fell below the $15 million minimum required under Listing Rule 5450(b) for the last 30 business days, triggering a non-compliance notice without immediate trading suspension.
2. Compliance Timeline and Requirements
Under Nasdaq Listing Rule 5810(c)(3)(D), Trinity has 180 calendar days, until August 18, 2026, to restore its MVPHS above $15 million for at least ten consecutive business days to regain compliance and maintain its Global Select Market listing.
3. Potential Delisting or Transfer Options
If Trinity fails to meet the requirement within the compliance period, it may seek a transfer to The Nasdaq Capital Market if eligible; otherwise, Nasdaq will initiate delisting procedures, though the company retains the right to appeal any delisting determination.